Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis

Shigeo Yoshizawa, Katsuyoshi Matsuoka, Nagamu Inoue, Hiromasa Takaishi, Haruhiko Ogata, Yasushi Iwao, Makio Mukai, Tomonobu Fujita, Yutaka Kawakami, Toshifumi Hibi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: For early detection of ulcerative colitis (UC)-associated colorectal cancer (CRC), surveillance colonoscopy is recommended in UC patients at high risk. However, poor acceptability deteriorates its effectiveness and a suitable marker for selecting patients at high risk is needed. Here we evaluated clinical usefulness of the measurement of anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera samples from UC patients. Methods: Sera from 286 patients with UC, 82 patients with sporadic CRC, and 63 healthy controls (HC) were obtained. Serum anti-p53 antibodies were detected with ELISA. Immunohistochemical detection was also performed in patients who developed dysplasia or CRC. Results: Serum p53 Ab was positive in 15.0% of UC, while it was positive only in 1.6% of HCs. In sporadic CRCs, 52.4% of 82 patients were positive. In UC patients with disease duration equal to or longer than 8 years, positivity of serum p53 Ab was significantly higher than those in patients with shorter duration. Eight of 13 (61.5%) UC patients with CRC or dysplasia were positive for serum p53 Abs, which was significantly higher than that in patients without neoplasia. All UC patients with CRC were positive for p53 staining, while 2 were negative for serum p53 Ab. Finally, levels of serum p53 Ab had fallen in 4 patients with CRC we could monitor after surgery. Conclusions: This study revealed that p53 Ab developed in the progression of UC-associated CRC but not in all patients with neoplasia, suggesting that serological detection of p53 Abs by ELISA is not suitable in primarily selecting patients at high risk; however, it is helpful in salvaging patients who drop from a surveillance program.

Original languageEnglish
Pages (from-to)865-873
Number of pages9
JournalInflammatory Bowel Diseases
Volume13
Issue number7
DOIs
Publication statusPublished - 2007 Jul

Fingerprint

Ulcerative Colitis
Carcinogenesis
Antibodies
Serum
Colorectal Neoplasms
Enzyme-Linked Immunosorbent Assay
Anti-Idiotypic Antibodies
Colonoscopy
Neoplasms

Keywords

  • Colorectal cancer
  • Enzyme-linked immunosorbent assay
  • p53
  • Surveillance
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. / Yoshizawa, Shigeo; Matsuoka, Katsuyoshi; Inoue, Nagamu; Takaishi, Hiromasa; Ogata, Haruhiko; Iwao, Yasushi; Mukai, Makio; Fujita, Tomonobu; Kawakami, Yutaka; Hibi, Toshifumi.

In: Inflammatory Bowel Diseases, Vol. 13, No. 7, 07.2007, p. 865-873.

Research output: Contribution to journalArticle

Yoshizawa, Shigeo ; Matsuoka, Katsuyoshi ; Inoue, Nagamu ; Takaishi, Hiromasa ; Ogata, Haruhiko ; Iwao, Yasushi ; Mukai, Makio ; Fujita, Tomonobu ; Kawakami, Yutaka ; Hibi, Toshifumi. / Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. In: Inflammatory Bowel Diseases. 2007 ; Vol. 13, No. 7. pp. 865-873.
@article{1805c07709ae4059b3dbd10af51216ba,
title = "Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis",
abstract = "Background: For early detection of ulcerative colitis (UC)-associated colorectal cancer (CRC), surveillance colonoscopy is recommended in UC patients at high risk. However, poor acceptability deteriorates its effectiveness and a suitable marker for selecting patients at high risk is needed. Here we evaluated clinical usefulness of the measurement of anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera samples from UC patients. Methods: Sera from 286 patients with UC, 82 patients with sporadic CRC, and 63 healthy controls (HC) were obtained. Serum anti-p53 antibodies were detected with ELISA. Immunohistochemical detection was also performed in patients who developed dysplasia or CRC. Results: Serum p53 Ab was positive in 15.0{\%} of UC, while it was positive only in 1.6{\%} of HCs. In sporadic CRCs, 52.4{\%} of 82 patients were positive. In UC patients with disease duration equal to or longer than 8 years, positivity of serum p53 Ab was significantly higher than those in patients with shorter duration. Eight of 13 (61.5{\%}) UC patients with CRC or dysplasia were positive for serum p53 Abs, which was significantly higher than that in patients without neoplasia. All UC patients with CRC were positive for p53 staining, while 2 were negative for serum p53 Ab. Finally, levels of serum p53 Ab had fallen in 4 patients with CRC we could monitor after surgery. Conclusions: This study revealed that p53 Ab developed in the progression of UC-associated CRC but not in all patients with neoplasia, suggesting that serological detection of p53 Abs by ELISA is not suitable in primarily selecting patients at high risk; however, it is helpful in salvaging patients who drop from a surveillance program.",
keywords = "Colorectal cancer, Enzyme-linked immunosorbent assay, p53, Surveillance, Ulcerative colitis",
author = "Shigeo Yoshizawa and Katsuyoshi Matsuoka and Nagamu Inoue and Hiromasa Takaishi and Haruhiko Ogata and Yasushi Iwao and Makio Mukai and Tomonobu Fujita and Yutaka Kawakami and Toshifumi Hibi",
year = "2007",
month = "7",
doi = "10.1002/ibd.20112",
language = "English",
volume = "13",
pages = "865--873",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis

AU - Yoshizawa, Shigeo

AU - Matsuoka, Katsuyoshi

AU - Inoue, Nagamu

AU - Takaishi, Hiromasa

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Mukai, Makio

AU - Fujita, Tomonobu

AU - Kawakami, Yutaka

AU - Hibi, Toshifumi

PY - 2007/7

Y1 - 2007/7

N2 - Background: For early detection of ulcerative colitis (UC)-associated colorectal cancer (CRC), surveillance colonoscopy is recommended in UC patients at high risk. However, poor acceptability deteriorates its effectiveness and a suitable marker for selecting patients at high risk is needed. Here we evaluated clinical usefulness of the measurement of anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera samples from UC patients. Methods: Sera from 286 patients with UC, 82 patients with sporadic CRC, and 63 healthy controls (HC) were obtained. Serum anti-p53 antibodies were detected with ELISA. Immunohistochemical detection was also performed in patients who developed dysplasia or CRC. Results: Serum p53 Ab was positive in 15.0% of UC, while it was positive only in 1.6% of HCs. In sporadic CRCs, 52.4% of 82 patients were positive. In UC patients with disease duration equal to or longer than 8 years, positivity of serum p53 Ab was significantly higher than those in patients with shorter duration. Eight of 13 (61.5%) UC patients with CRC or dysplasia were positive for serum p53 Abs, which was significantly higher than that in patients without neoplasia. All UC patients with CRC were positive for p53 staining, while 2 were negative for serum p53 Ab. Finally, levels of serum p53 Ab had fallen in 4 patients with CRC we could monitor after surgery. Conclusions: This study revealed that p53 Ab developed in the progression of UC-associated CRC but not in all patients with neoplasia, suggesting that serological detection of p53 Abs by ELISA is not suitable in primarily selecting patients at high risk; however, it is helpful in salvaging patients who drop from a surveillance program.

AB - Background: For early detection of ulcerative colitis (UC)-associated colorectal cancer (CRC), surveillance colonoscopy is recommended in UC patients at high risk. However, poor acceptability deteriorates its effectiveness and a suitable marker for selecting patients at high risk is needed. Here we evaluated clinical usefulness of the measurement of anti-p53 antibodies (Abs) by enzyme-linked immunosorbent assay (ELISA) using sera samples from UC patients. Methods: Sera from 286 patients with UC, 82 patients with sporadic CRC, and 63 healthy controls (HC) were obtained. Serum anti-p53 antibodies were detected with ELISA. Immunohistochemical detection was also performed in patients who developed dysplasia or CRC. Results: Serum p53 Ab was positive in 15.0% of UC, while it was positive only in 1.6% of HCs. In sporadic CRCs, 52.4% of 82 patients were positive. In UC patients with disease duration equal to or longer than 8 years, positivity of serum p53 Ab was significantly higher than those in patients with shorter duration. Eight of 13 (61.5%) UC patients with CRC or dysplasia were positive for serum p53 Abs, which was significantly higher than that in patients without neoplasia. All UC patients with CRC were positive for p53 staining, while 2 were negative for serum p53 Ab. Finally, levels of serum p53 Ab had fallen in 4 patients with CRC we could monitor after surgery. Conclusions: This study revealed that p53 Ab developed in the progression of UC-associated CRC but not in all patients with neoplasia, suggesting that serological detection of p53 Abs by ELISA is not suitable in primarily selecting patients at high risk; however, it is helpful in salvaging patients who drop from a surveillance program.

KW - Colorectal cancer

KW - Enzyme-linked immunosorbent assay

KW - p53

KW - Surveillance

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=34547628663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547628663&partnerID=8YFLogxK

U2 - 10.1002/ibd.20112

DO - 10.1002/ibd.20112

M3 - Article

C2 - 17285596

AN - SCOPUS:34547628663

VL - 13

SP - 865

EP - 873

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 7

ER -